Mayo Clinic · Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Nat Rev Clin Oncol, Jan 2026Diagnosis, risk stratification and management of smouldering multiple myeloma.
Research view
Multiple myeloma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- BCMA 134
- CD38 22
- GPRC5D 36
- CD19 31
- TP53 0
- STAT3 0
- CXCR4 4
- MYC 0
- BCL-2 2
- PI3K 1
- mTOR 0
- IL-6 0
- STING 0
- BRAF 2
- CD47 1
- HDAC 0
- AKT 0
- PD-1 1
- PD-L1 1
- CD20 3
- GLP-1 0
- JAK 0
- PTEN 0
- SGLT2 0
- AMPK 0
- B7-H3 0
- NRAS 1
- TIGIT 0
- CTLA-4 1
- ERK 0
- EZH2 0
- FTO 0
- IL-15 3
- JNK 0
- KRAS 1
- MAPK 0
- RAS 0
- CD22 2
- CD33 1
- CTNNB1 0
- EGFR 0
- FGFR 0
- LAG-3 0
- MDM2 0
- METTL3 0
- NRF2 0
- BRCA1 0
- BRD4 0
- BTK 1
- CD123 1
- CD30 0
- CDK4/6 0
- GPX4 0
- HER2 0
- HIF-1 0
- HSP90 0
- MEK 0
- MET 0
- MUC1 0
- NTRK 0
EU-13 is a filter, not a ranking: it only narrows the list.
New York, United States
Boston, United States
Harvard University · Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Mil Med Res, Nov 2025Diverging global incidence trends of early-onset cancers: comparisons with incidence trends of later-onset cancers and mortality trends of early-onset cancers.
New Brunswick, United States
The University of Texas MD Anderson Cancer Center · Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Eur J Haematol, Jan 2026Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.
Athens, Greece
Würzburg, Germany
Moffitt Cancer Center · Tampa, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Adv, Mar 2026Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.
New York, United States
Pamplona, Spain
Paris, France
Cleveland, United States
Seattle, United States
Atlanta, United States
Salamanca, Spain
Milwaukee, United States
Bologna, Italy
Birmingham, United States
Nantes, France
Hamburg, Germany
Duarte, United States
The University of Texas Southwestern Medical Center · Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Blood Cancer J, Jan 2026Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.
Melbourne, Australia
24 of 1,872 institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
“Administrative hold pending non-safety related changes to the study design.”Registry text, quoted unchanged. Source
Terminated
Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma
“Funding/ transfer PI”Registry text, quoted unchanged. Source
Terminated
“Operational limitations”Registry text, quoted unchanged. Source
Suspended
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
“Scheduled Interim Monitoring”Registry text, quoted unchanged. Source
Terminated
64Cu-LLP2A for Imaging Hematologic Malignancies
“Loss of further funding”Registry text, quoted unchanged. Source
Suspended
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
“The study was not started because the necessary resources could not yet be secured after COVID-19, which was the reason for the initial interruption of the study.”Registry text, quoted unchanged. Source
Suspended
“pending amendment”Registry text, quoted unchanged. Source
Suspended
“Enrollment to Dose Level 1 cohort has been met”Registry text, quoted unchanged. Source
Terminated
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
“Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts”Registry text, quoted unchanged. Source
Withdrawn
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
“Due to barriers in anticipated accrual”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 23
- Organoids 3
- Mendelian Randomization Analysis 10
- CRISPR-Cas Systems 8
- Gene Expression Profiling 44
- Sequence Analysis, RNA 7
- Whole Genome Sequencing 4
- Exome Sequencing 3
- Proteomics 15
- Metabolomics 10
- Mass Spectrometry 7
- Flow Cytometry 48
- Immunohistochemistry 11
- Liquid Biopsy 2
- Circulating Tumor DNA 2
- Xenograft Model Antitumor Assays 78
- Positron-Emission Tomography 14
- Magnetic Resonance Imaging 26
- Machine Learning 17
- Deep Learning 6
- Cohort Studies 32
- Genome-Wide Association Study 7
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.